Dame Lesley Fallowfield

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7457276/publications.pdf

Version: 2024-02-01

302 papers 34,582 citations

90 h-index 179 g-index

318 all docs

318 docs citations

318 times ranked

25379 citing authors

#	Article	IF	Citations
1	A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. New England Journal of Medicine, 2004, 350, 1081-1092.	13.9	1,694
2	Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial. Journal of the National Cancer Institute, 2006, 98, 599-609.	3.0	1,422
3	4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 2018, 29, 1634-1657.	0.6	891
4	3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33.	0.6	865
5	Communicating sad, bad, and difficult news in medicine. Lancet, The, 2004, 363, 312-319.	6.3	839
6	Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup) Tj ETQq	0 <u>0 0</u> rgB1	「 Qverlock 1(
7	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2016, 387, 945-956.	6.3	791
8	Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. Lancet, The, 2002, 359, 650-656.	6.3	780
9	Ovarian cancer. Nature Reviews Disease Primers, 2016, 2, 16061.	18.1	761
10	5th ESO-ESMO international consensus guidelines for advanced breastÂcancer (ABC 5). Annals of Oncology, 2020, 31, 1623-1649.	0.6	761
11	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, The, 2009, 10, 327-340.	5.1	738
12	Information needs of patients with cancer: results from a large study in UK cancer centres. British Journal of Cancer, 2001, 84, 48-51.	2.9	684
13	Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial BMJ: British Medical Journal, 1990, 301, 575-580.	2.4	656
14	Psychiatric morbidity and its recognition by doctors in patients with cancer. British Journal of Cancer, 2001, 84, 1011-1015.	2.9	581
15	Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. European Journal of Cancer, 2000, 36, 1938-1943.	1.3	554
16	Multidisciplinary teams in cancer care: are they effective in the UK?. Lancet Oncology, The, 2006, 7, 935-943.	5.1	505
17	Information needs of cancer patients in west Scotland: cross sectional survey of patients' views. BMJ: British Medical Journal, 1996, 313, 724-726.	2.4	478
18	Effective communication skills are the key to good cancer care. European Journal of Cancer, 1999, 35, 1592-1597.	1.3	453

#	Article	IF	Citations
19	Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Research and Treatment, 2006, 95, 279-293.	1.1	432
20	Truth may hurt but deceit hurts more: communication in palliative care. Palliative Medicine, 2002, 16, 297-303.	1.3	408
21	The psychological impact of immediate rather than delayed breast reconstruction. European Journal of Surgical Oncology, 2000, 26, 17-19.	0.5	405
22	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Annals of Oncology, 2014, 25, 1871-1888.	0.6	402
23	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii11-vii19.	0.6	400
24	Doctor-patient interactions in oncology. Social Science and Medicine, 1996, 42, 1511-1519.	1.8	347
25	Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom Journal of Clinical Oncology, 1998, 16, 1961-1968.	0.8	322
26	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2021, 397, 2182-2193.	6.3	313
27	Intentional and non-intentional non-adherence to medication amongst breast cancer patients. European Journal of Cancer, 2006, 42, 2271-2276.	1.3	311
28	Enduring impact of communication skills training: results of a 12-month follow-up. British Journal of Cancer, 2003, 89, 1445-1449.	2.9	298
29	Effects of breast conservation on psychological morbidity associated with diagnosis and treatment of early breast cancer BMJ: British Medical Journal, 1986, 293, 1331-1334.	2.4	295
30	The Sexual Activity Questionnaire: A measure of women's sexual functioning. Quality of Life Research, 1996, 5, 81-90.	1.5	293
31	Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. British Journal of Cancer, 2003, 88, 666-671.	2.9	293
32	1st International consensus guidelines for advanced breast cancer (ABC 1). Breast, 2012, 21, 242-252.	0.9	291
33	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACTâ€B. Breast Cancer Research and Treatment, 1999, 55, 187-197.	1.1	285
34	Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 2004, 22, 4261-4271.	0.8	283
35	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast, 2014, 23, 489-502.	0.9	269
36	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2011, 22, vi25-vi30.	0.6	266

#	Article	IF	CITATIONS
37	Addressing overtreatment of screen detected DCIS; the LORIS trial. European Journal of Cancer, 2015, 51, 2296-2303.	1.3	266
38	Giving sad and bad news. Lancet, The, 1993, 341, 476-478.	6.3	261
39	Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. British Journal of Cancer, 2000, 82, 1783-1788.	2.9	258
40	Rasch fit statistics and sample size considerations for polytomous data. BMC Medical Research Methodology, 2008, 8, 33.	1.4	248
41	Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Research and Treatment, 2008, 107, 167-180.	1.1	232
42	Quality of Life of Postmenopausal Women in the ATAC ("Arimidexâ€, Tamoxifen, Alone or in) Tj ETQq0 0 0 rgE Cancer Research and Treatment, 2006, 100, 273-284.	BT /Overloo 1.1	ck 10 Tf 50 5 218
43	No news is not good news: Information preferences of patients with cancer. Psycho-Oncology, 1995, 4, 197-202.	1.0	216
44	Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials. Journal of Clinical Oncology, 2001, 19, 1885-1892.	0.8	214
45	Can oncologists detect distress in their out-patients and how satisfied are they with their performance during bad news consultations?. British Journal of Cancer, 1994, 70, 767-770.	2.9	202
46	International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. Journal of the National Cancer Institute, 2009, 101, 1174-1181.	3.0	202
47	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology, 2004, 13, 61-66.	1.0	195
48	Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity?. European Journal of Surgical Oncology, 1999, 25, 571-573.	0.5	194
49	Can Communication Skills Training Alter Physicians' Beliefs and Behavior in Clinics?. Journal of Clinical Oncology, 2002, 20, 765-769.	0.8	188
50	Psychological effects of being offered choice of surgery for breast cancer. BMJ: British Medical Journal, 1994, 309, 448-448.	2.4	183
51	Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer. Journal of Clinical Oncology, 2006, 24, 910-917.	0.8	180
52	Missing quality of life data in cancer clinical trials: serious problems and challenges., 1998, 17, 517-532.		176
53	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncology, The, 2011, 12, 38-48.	5.1	176
54	Information needs and experiences: An audit of UK cancer patients. European Journal of Oncology Nursing, 2006, 10, 263-272.	0.9	175

#	Article	IF	Citations
55	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncology, The, 2013, 14, 962-970.	5.1	173
56	Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncology, The, 2008, 9, 1143-1148.	5.1	171
57	3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259.	0.9	171
58	Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology, 2012, 14, 392-404.	0.6	166
59	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Journal of Clinical Oncology, 2015, 33, 2062-2071.	0.8	166
60	Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009. Annals of Oncology, 2010, 21, 204-207.	0.6	163
61	Lay understanding of terms used in cancer consultations. Psycho-Oncology, 2003, 12, 557-566.	1.0	156
62	Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncology, The, 2008, 9, 884-891.	5.1	156
63	Tumor Boards: Optimizing the Structure and Improving Efficiency of Multidisciplinary Management of Patients with Cancer Worldwide. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e461-e466.	1.8	156
64	Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Supportive Care in Cancer, 2020, 28, 4589-4612.	1.0	156
65	Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Annals of Oncology, 2006, 17, 205-210.	0.6	151
66	Treatment decision-making in breast cancer: the patient–doctor relationship. Breast Cancer Research and Treatment, 2008, 112, 5-13.	1.1	149
67	Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials, 2019, 20, 718.	0.7	148
68	Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer?. European Journal of Cancer, 1999, 35, 79-85.	1.3	147
69	Factors affecting patient and clinician satisfaction with the clinical consultation: Can communication skills training for clinicians improve satisfaction?. Psycho-Oncology, 2003, 12, 599-611.	1.0	144
70	Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016, 26, 87-99.	0.9	142
71	The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured. BMJ: British Medical Journal, 2001, 322, 76-76.	2.4	140
72	The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively. Breast Cancer Research and Treatment, 2001, 68, 273-282.	1.1	138

#	Article	IF	Citations
73	The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Annals of Oncology, 2022, 33, 878-892.	0.6	133
74	Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study. BMJ: British Medical Journal, 2008, 337, a2079-a2079.	2.4	128
75	What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial Discussions. Journal of Clinical Oncology, 2011, 29, 61-68.	0.8	126
76	Pain outcomes in patients with advanced breast cancer and bone metastases. Cancer, 2013, 119, 832-838.	2.0	126
77	The effects of hormone therapy on cognition in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 405-412.	1.2	125
78	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. Clinical Cancer Research, 2012, 18, 4841-4849.	3.2	124
79	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals of Oncology, 2014, 25, 1979-1987.	0.6	122
80	Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. British Journal of Cancer, 2002, 87, 1341-1353.	2.9	116
81	Attitudes of patients to randomised clinical trials of cancer therapy. European Journal of Cancer, 1998, 34, 1554-1559.	1.3	114
82	The Medical Interaction Process System (MIPS): an instrument for analysing interviews of oncologists and patients with cancer. Social Science and Medicine, 2000, 50, 553-566.	1.8	114
83	Pulmonary Metastasectomy in Colorectal Cancer: The PulMiCC Trial. Journal of Thoracic Oncology, 2010, 5, \$203-\$206.	0.5	112
84	Clinicians' attitudes to clinical trials of cancer therapy. European Journal of Cancer, 1997, 33, 2221-2229.	1.3	109
85	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncology, The, 2008, 9, 953-961.	5.1	108
86	The efficacy of audiotapes in promoting psychological well-being in cancer patients: a randomised, controlled trial. British Journal of Cancer, 1995, 71, 388-392.	2.9	101
87	How do doctors explain randomised clinical trials to their patients?. European Journal of Cancer, 1999, 35, 1187-1193.	1.3	101
88	Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial: Figure 1. Thorax, 2012, 67, 185-187.	2.7	100
89	Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study. BMJ: British Medical Journal, 2001, 323, 836-837.	2.4	98
90	Psychosocial/Survivorship Issues in Breast Cancer: Are We Doing Better?. Journal of the National Cancer Institute, 2014, 107, dju335-dju335.	3.0	96

#	Article	IF	Citations
91	Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. Patient, 2015, 8, 145-153.	1.1	96
92	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v15-v19.	0.6	95
93	Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for †well-tolerated' treatments?. Breast Cancer Research and Treatment, 2001, 66, 73-81.	1.1	92
94	Participation of patients in decisions about treatment for cancer. BMJ: British Medical Journal, 2001, 323, 1144-1144.	2.4	91
95	Quality of life: a new perspective for cancer patients. Nature Reviews Cancer, 2002, 2, 873-879.	12.8	89
96	Psychological morbidity in newly referred patients with cancer. Journal of Psychosomatic Research, 1995, 39, 193-202.	1.2	86
97	Epoetin alfa improves quality of life in patients with cancer. Cancer, 2004, 101, 1720-1732.	2.0	85
98	Are members of multidisciplinary teams in breast cancer aware of each other's informational roles?. Quality in Health Care: QHC, 2001, 10, 70-75.	1.2	84
99	The informational roles and psychological health of members of 10 oncology multidisciplinary teams in the UK. British Journal of Cancer, 2005, 93, 1092-1097.	2.9	84
100	Current state of quality of life and patient-reported outcomes research. European Journal of Cancer, 2019, 121, 55-63.	1.3	83
101	ARIX: A randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer. Annals of Oncology, 2013, 24, 776-783.	0.6	82
102	Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 2013, 21, 3497-3507.	1.0	80
103	Teaching Senior Nurses How to Teach Communication Skills in Oncology. Cancer Nursing, 2001, 24, 185-191.	0.7	78
104	Drivers and barriers to patient participation in RCTs. British Journal of Cancer, 2013, 108, 1402-1407.	2.9	78
105	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast, 2013, 22, 203-210.	0.9	77
106	Sentinel lymph node biopsy in male breast cancer patients. European Journal of Surgical Oncology, 2004, 30, 480-483.	0.5	75
107	Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research UK training programme. BMJ: British Medical Journal, 2005, 330, 400.	2.4	75
108	The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. British Journal of Cancer, 2010, 103, 1801-1807.	2.9	75

#	Article	IF	Citations
109	Offering choice of surgical treatment to women with breast cancer. Patient Education and Counseling, 1997, 30, 209-214.	1.0	74
110	The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ. Clinical Oncology, 2015, 27, 6-8.	0.6	74
111	Communication and informed consent in phase 1 trials: a review of the literature. Supportive Care in Cancer, 2006, 14 , $303-309$.	1.0	70
112	Can we improve the professional and personal fulfilment of doctors in cancer medicine?. British Journal of Cancer, 1995, 71, 1132-1133.	2.9	64
113	Truth Sometimes Hurts but Deceit Hurts More. Annals of the New York Academy of Sciences, 1997, 809, 525-536.	1.8	62
114	Psychosexual function and impact of gynaecological cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2007, 21, 309-320.	1.4	62
115	Information preferences of patients with cancer. Lancet, The, 1994, 344, 1576.	6.3	61
116	Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive Care in Cancer, 2016, 24, 1327-1337.	1.0	61
117	Reasons given by patients for participating, or not, in Phase 1 cancer trials. European Journal of Cancer, 2011, 47, 1490-1497.	1.3	60
118	Results of an intervention study to improve communication about randomised clinical trials of cancer therapy. European Journal of Cancer, 2001, 37, 322-331.	1.3	58
119	The value of progression-free survival to patients with advanced-stage cancer. Nature Reviews Clinical Oncology, 2012, 9, 41-47.	12.5	58
120	Quality of quality-of-life data. Lancet, The, 1996, 348, 421-422.	6.3	57
121	Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology, 2004, 72, 199-211.	0.3	56
122	A qualitative study looking at the psychosocial implications of bilateral prophylactic mastectomy. Breast, 2003, 12, 1-9.	0.9	55
123	Patient-reported outcome measures of the impact of cancer on patients' everyday lives: a systematic review. Journal of Cancer Survivorship, 2017, 11, 211-232.	1.5	55
124	Current Concepts of Communication Skills Training in Oncology. , 2006, 168, 105-112.		53
125	Patient evaluation of cosmetic outcome after conserving surgery for treatment of primary breast cancer. European Journal of Surgical Oncology, 1999, 25, 344-346.	0.5	52
126	Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (†Arimidex',) Tj ETQq0	O 20 97 gBT	/O se rlock 10

#	Article	IF	Citations
127	A Rasch and confirmatory factor analysis of the General Health Questionnaire (GHQ) - 12. Health and Quality of Life Outcomes, 2010, 8, 45.	1.0	51
128	Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?. British Journal of Cancer, 2011, 105, 1260-1266.	2.9	51
129	The treatment of early breast cancer in women over the age of 70. British Journal of Cancer, 2011, 105, 189-193.	2.9	50
130	The pervasive nature of uncertaintyâ€"a qualitative study of patients with advanced cancer and their informal caregivers. Journal of Cancer Survivorship, 2017, 11, 590-603.	1.5	50
131	Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Annals of Oncology, 2012, 23, 3045-3051.	0.6	48
132	Acceptance of adjuvant therapy and quality of life issues. Breast, 2005, 14, 612-616.	0.9	47
133	Patient-reported outcome measures for cancer caregivers: a systematic review. Quality of Life Research, 2016, 25, 1859-1876.	1.5	47
134	Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. British Journal of Cancer, 2012, 106, 1062-1067.	2.9	46
135	Assessment of Quality of Life in Breast Cancer. Acta Oncológica, 1995, 34, 689-694.	0.8	45
136	A daily diary for quality of life measurement in advanced breast cancer trials. British Journal of Cancer, 1993, 67, 341-346.	2.9	44
137	Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?. British Journal of Cancer, 2005, 93, 1319-1323.	2.9	43
138	Pulmonary metastasectomy in colorectal cancer: Time for a trial. European Journal of Surgical Oncology, 2009, 35, 686-689.	0.5	43
139	Self-reported sexual health: Breast cancer survivors compared to women from the general population – an observational study. BMC Cancer, 2017, 17, 599.	1.1	43
140	The Pulmonary Metastasectomy in Colorectal Cancer cohort study: Analysis of case selection, risk factors and survival in a prospective observational study of 512 patients. Colorectal Disease, 2021, 23, 1793-1803.	0.7	43
141	Psychosocial interventions in cancer. BMJ: British Medical Journal, 1995, 311, 1316-1317.	2.4	43
142	Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. European Journal of Cancer, 2004, 40, 2403-2410.	1.3	42
143	Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making. Psycho-Oncology, 2013, 22, 2729-2735.	1.0	42
144	Florence statement on breast cancer, 1998. European Journal of Cancer, 1999, 35, 14-15.	1.3	41

#	Article	IF	CITATIONS
145	Sexual activity questionnaires in clinical trials: acceptability to patients with gynaecological disorders. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 50-54.	1.1	40
146	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. Trials, 2011, 12, 61.	0.7	40
147	Clinicians' attitudes towards clinical trials of cancer therapy. British Journal of Cancer, 2011, 104, 1535-1543.	2.9	40
148	Counselling for patients with cancer BMJ: British Medical Journal, 1988, 297, 727-728.	2.4	39
149	Describing randomisation: patients' and the public's preferences compared with clinicians' practice. British Journal of Cancer, 2002, 87, 854-858.	2.9	39
150	Psychological morbidity associated with ovarian cancer screening: results from more than 23Â000 women in the randomised trial of ovarian cancer screening (<scp>UKCTOCS</scp>). BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 1071-1079.	1.1	39
151	Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. European Journal of Cancer, 2017, 86, 82-90.	1.3	39
152	Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. Annals of Oncology, 2013, 24, 1211-1219.	0.6	38
153	The effects of oestrogens and anti-oestrogens on cognition. Breast, 2001, 10, 484-491.	0.9	37
154	After going through chemotherapy I can't see another needle. European Journal of Oncology Nursing, 2007, 11, 43-48.	0.9	36
155	Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation. Climacteric, 2015, 18, 94-98.	1.1	33
156	Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Annals of Oncology, 2016, 27, 2046-2052.	0.6	33
157	The use of denial in an ethnically diverse British cancer population: a cross-sectional study. British Journal of Cancer, 2005, 92, 1393-1397.	2.9	31
158	Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Supportive Care in Cancer, 2015, 23, 1157-1168.	1.0	31
159	Anxiety and support in breast cancer: is this different for affluent and deprived women? A questionnaire study. British Journal of Cancer, 2004, 91, 879-883.	2.9	30
160	Evolution of breast cancer treatments: current options and quality-of-life considerations. European Journal of Oncology Nursing, 2004, 8, S75-S82.	0.9	30
161	Fallowfield's Sexual Activity Questionnaire in women with without and at risk of cancer. Menopause International, 2007, 13, 103-109.	1.6	30
162	Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition?. European Journal of Cancer, 2007, 43, 1342-1347.	1.3	30

#	Article	IF	Citations
163	Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of $21\hat{a} \in \%715$ women participating in the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer, 2010, 103, 454-461.	2.9	30
164	Teaching senior nurses how to teach communication skills in oncology. Cancer Nursing, 2001, 24, 185-91.	0.7	30
165	Psychological outcome of treatment for early breast cancer: A review. Stress and Health, 1989, 5, 167-175.	0.6	29
166	When Breast Cancer Recurs: A 3-Year Prospective Study of Psychological Morbidity. Breast Journal, 1996, 2, 197-203.	0.4	29
167	Group Acupuncture to Relieve Radiation Induced Xerostomia: A Feasibility Study. Acupuncture in Medicine, 2009, 27, 109-113.	0.4	29
168	Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study. British Journal of Cancer, 2013, 108, 2264-2271.	2.9	29
169	The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British Journal of Cancer, 2017, 117, 619-627.	2.9	29
170	Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the â€~no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology, 2020, 158, 316-322.	0.6	29
171	POSNOCâ€"POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open, 2021, 11, e054365.	0.8	29
172	Evaluation of an Educational Program to Improve Communication with Patients About Early-Phase Trial Participation. Oncologist, 2012, 17, 377-383.	1.9	28
173	The psychological impact of post-operative arm morbidity following axillary surgery for breast cancer: a critical review. Breast, 2002, 11, 81-87.	0.9	27
174	Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 643-650.	12.5	27
175	The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397). BJU International, 2007, 99, 301-310.	1.3	26
176	Quality of Life and Patient-reported Outcomes in the Older Breast Cancer Patient. Clinical Oncology, 2009, 21, 140-155.	0.6	26
177	Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009. Supportive Care in Cancer, 2010, 18 , $1115-1121$.	1.0	26
178	Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics". Journal of the National Cancer Institute, 2014, 106, dju321-dju321.	3.0	26
179	Living with metastatic breast cancer: a global patient survey. Community Oncology, 2010, 7, 406-412.	0.2	24
180	Pulmonary metastasectomy in colorectal cancer: health utility scores by EQâ€5Dâ€3L in a randomized controlled trial show no benefit from lung metastasectomy. Colorectal Disease, 2021, 23, 200-205.	0.7	24

#	Article	IF	CITATIONS
181	Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. Supportive Care in Cancer, 2017, 25, 237-244.	1.0	23
182	Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 2017, 35, 2507-2514.	0.8	22
183	What are the psychological factors influencing attendance, non-attendance and re-attendance at a breast screening centre?. Journal of the Royal Society of Medicine, 1990, 83, 547-51.	1.1	22
184	Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer, 2005, 48, 365-377.	0.9	21
185	Communication skills training for breast cancer teams talking about trials. Breast, 2014, 23, 193-197.	0.9	21
186	Teams Talking Trials: Results of an RCT to improve the communication of cancer teams about treatment trials. Contemporary Clinical Trials, 2013, 35, 43-51.	0.8	20
187	Low grade Ductal Carcinoma in situ (DCIS): How best to describe it?. Breast, 2014, 23, 693-696.	0.9	20
188	Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study. Breast, 2015, 24, 166-170.	0.9	20
189	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. Menopause, 2019, 26, 1100-1009.	0.8	20
190	Questionnaire design Archives of Disease in Childhood, 1995, 72, 76-79.	1.0	19
191	Things to consider when teaching doctors how to deliver good, bad and sad news. Medical Teacher, 1996, 18, 27-30.	1.0	19
192	What non-prescription treatments do UK women with breast cancer use?. European Journal of Cancer Care, 2006, 15, 279-285.	0.7	19
193	Patients' decision-making in a UK specialist centre with high mastectomy rates. Breast, 2008, 17, 574-579.	0.9	19
194	Patient–physician interactions during early breast-cancer treatment: results from an international online survey. Current Medical Research and Opinion, 2008, 24, 1891-1904.	0.9	19
195	Time for a low-risk DCIS trial: harnessing public and patient involvement. Lancet Oncology, The, 2012, 13, 1183-1185.	5.1	19
196	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Annals of Oncology, 2019, 30, 567-574.	0.6	19
197	Quality of life issues in relation to the aromatase inhibitor. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 168-172.	1.2	18
198	Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. Supportive Care in Cancer, 2012, 20, 657-677.	1.0	18

#	Article	IF	Citations
199	Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Ultrasound in Obstetrics and Gynecology, 2013, 41, 73-79.	0.9	18
200	Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. European Journal of Cancer, 2021, 152, 223-232.	1.3	18
201	Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial. Journal of Clinical Oncology, 2005, 23, 577-577.	0.8	18
202	Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Research and Treatment, 2011, 125, 741-749.	1.1	17
203	The myth of pulmonary metastasectomy. British Journal of Cancer, 2020, 123, 499-500.	2.9	17
204	Anxiety in women "at risk' of developing breast cancer. British Journal of Cancer, 1996, 73, 1422-1424.	2.9	16
205	Quality of life assessment using patient-reported outcome (PRO) measures: still a Cinderella outcome?. Annals of Oncology, 2018, 29, 2286-2287.	0.6	16
206	Gaps in Care and Support for Patients With Advanced Breast Cancer: A Report From the Advanced Breast Cancer Global Alliance. JCO Global Oncology, 2021, 7, 976-984.	0.8	16
207	Communication with the cancer patient:How to improve the communication skills of oncologists. Annals of Oncology, 2000, $11,63-68$.	0.6	15
208	Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. Breast, 2017, 34, 89-95.	0.9	15
209	Information provision for patients by breast cancer teams about the side-effects of hormone treatments. European Journal of Cancer, 2006, 42, 1760-1767.	1.3	14
210	Sun-Protective Behaviors in Families at Increased Risk of Melanoma. Journal of Investigative Dermatology, 2007, 127, 1343-1350.	0.3	14
211	Blurring of boundaries in the doctor–patient relationship. Lancet Oncology, The, 2014, 15, 1423-1424.	5.1	14
212	Delivering bad news in gastroenterology. American Journal of Gastroenterology, 1994, 89, 473-9.	0.2	14
213	The preferences of 600 patients for different descriptions of randomisation. British Journal of Cancer, 2005, 92, 807-810.	2.9	13
214	There's many a slip twixt cup and lip: adherence issues in cancer therapy. Nature Clinical Practice Oncology, 2008, 5, 118-119.	4.3	13
215	Cancer counselling in the United Kingdom. Psychology and Health, 1992, 6, 107-117.	1.2	12
216	The impact of endocrine therapy on patients with breast cancer: a review of the literature. Breast, 2002, 11, 1-12.	0.9	12

#	Article	IF	CITATIONS
217	Communication with Patients after Errors. Journal of Health Services Research and Policy, 2010, 15, 56-59.	0.8	12
218	Overtreatment of Low-Grade Ductal Carcinoma In Situ. JAMA Oncology, 2016, 2, 382.	3.4	12
219	Enhancing decisionâ€making about adjuvant chemotherapy in early breast cancer following EndoPredict testing. Psycho-Oncology, 2018, 27, 1264-1269.	1.0	12
220	Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study. Clinical Oncology, 2019, 31, 99-107.	0.6	12
221	The ideal consultation. British Journal of Hospital Medicine, 1992, 47, 364-7.	0.0	12
222	Quality of Life in the Elderly Woman with Breast Cancer Treated with Tamoxifen and Surgery or Tamoxifen Alone. Journal of Women's Health, 1994, 3, 17-20.	0.9	11
223	Has Psychosocial Oncology Helped in the Management of Women with Breast Cancer?. Breast Journal, 1996, 2, 107-113.	0.4	11
224	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). Lancet, The, 1998, 352, 1222.	6.3	11
225	A UKâ€wide survey of followâ€up practices for patients with highâ€grade glioma treated with radical intent. Journal of Evaluation in Clinical Practice, 2011, 17, 1-6.	0.9	11
226	Development and validation of the patient roles and responsibilities scale in cancer patients. Quality of Life Research, 2018, 27, 2923-2934.	1.5	11
227	Learning how to communicate in cancer settings. Supportive Care in Cancer, 2005, 13, 349-350.	1.0	10
228	Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 954-957.	1.1	10
229	The challenge of interacting with patients in oncology. European Journal of Cancer, 2009, 45, 445-446.	1.3	10
230	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. International Journal of Gynecological Cancer, 2015, 25, 1519-1525.	1.2	10
231	Contraceptive use by women receiving chemotherapy for breast cancer. Breast, 1998, 7, 143-149.	0.9	9
232	The preferences and experiences of different bisphosphonate treatments in women with breast cancer. Psycho-Oncology, 2011, 20, 755-761.	1.0	9
233	Supportive follow-up in patients treated with radical intent for high-grade glioma. CNS Oncology, 2012, 1, 39-48.	1.2	9
234	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. Annals of Surgical Oncology, 2017, 24, 566-567.	0.7	9

#	Article	IF	CITATIONS
235	Development and validation of the caregiver roles and responsibilities scale in cancer caregivers. Quality of Life Research, 2019, 28, 1655-1668.	1.5	9
236	A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer. Breast Cancer Research and Treatment, 2020, 183, 9-21.	1.1	9
237	NICE Guidelines: management of colorectal cancer metastases. British Journal of Surgery, 2020, 107, e357-e357.	0.1	9
238	The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) burden of care study: Analysis of local treatments for lung metastases and systemic chemotherapy in 220 patients in the PulMiCC cohort. Colorectal Disease, 2021, 23, 2911-2922.	0.7	9
239	Quality of life measurement in breast cancer. Journal of the Royal Society of Medicine, 1993, 86, 10-2.	1.1	9
240	The impact of hormone replacement therapy on breast cancer patients' quality of life and sexuality: a pilot study. The Journal of the British Menopause Society, 2001, 7, 85-91.	1.3	8
241	Acronymic trials: the good, the bad, and the coercive. Lancet, The, 2002, 360, 1622.	6.3	8
242	The views of patients and the general public about expensive anti-cancer drugs in the NHS: a questionnaire-based study. JRSM Short Reports, 2011, 2, 1-8.	0.6	8
243	The need to determine whether lung metastasectomy improves survival in advanced colorectal cancer. BMJ, The, 2014, 348, g4085-g4085.	3.0	8
244	For the Benefit of Others: Reasons Why Women with Breast Cancer Participate in RCTs. Breast Care, 2015, 10, 88-93.	0.8	8
245	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. British Journal of Cancer, 2017, 116, 1111-1117.	2.9	8
246	Quality of survival: a new concept framework to assess the quality of prolonged life in cancer. Expert Review of Quality of Life in Cancer Care, 2017, 2, 225-232.	0.6	8
247	Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the †VALue' to patients of PROgression Free Survival) study. Supportive Care in Cancer, 2018, 26, 3941-3949.	1.0	8
248	Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey. Breast, 2008, 17, 459-463.	0.9	7
249	Sexual Dysfunction in Breast Cancer Survivors: Cross-Cultural Adaptation of the Sexual Activity Questionnaire for Use in Portugal. Acta Medica Portuguesa, 2016, 29, 533-541.	0.2	7
250	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trialsâ€"an ovarian cancer exemplar. Trials, 2021, 22, 88.	0.7	7
251	Sentinel node biopsy in breast cancer: The first results of the randomized multicenter ALMANAC Trial. Journal of Clinical Oncology, 2004, 22, 506-506.	0.8	7
252	Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer. Current Medical Research and Opinion, 2005, 21, 1329-1335.	0.9	6

#	Article	IF	Citations
253	Randomized Controlled Trial of Pulmonary Metastasectomy in Colorectal Cancer: PulMiCC International Is Open in Italy. Oncologist, 2013, 18, 637-637.	1.9	6
254	Effects of Standard Treatments for Ductal Carcinoma In Situ—Making Informed Choices. JAMA Oncology, 2016, 2, 396.	3.4	6
255	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancers, 2021, 13, 858.	1.7	6
256	A structured review of quality of life in advanced and highâ€risk cutaneous squamous cell carcinoma shows the need for more studies and better measures. Skin Health and Disease, 2021, 1, e39.	0.7	6
257	Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM) Journal of Clinical Oncology, 2014, 32, 12-12.	0.8	6
258	Evaluation of Counselling in the National Health Service. Journal of the Royal Society of Medicine, 1993, 86, 429-430.	1.1	6
259	Sexuality in women receiving chemotherapy for breast cancer. Annals of Oncology, 1997, 8, 616-617.	0.6	5
260	Clinical trials to real life: the relevance of quality of life. Pharmaceutical Medicine, 2000, 14, 82-84.	0.4	5
261	Group recruitment sessions enhance patient understanding in a small multi-centre phase III clinical trial. Contemporary Clinical Trials, 2012, 33, 286-290.	0.8	5
262	No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer. Supportive Care in Cancer, 2016, 24, 4471-4473.	1.0	5
263	Talking about risk in the context of genomic tests (TARGET): development and evaluation of an educational program for clinicians. Breast Cancer Research and Treatment, 2019, 177, 641-649.	1.1	5
264	Sentinel node biopsy in breast cancer: The first results of the randomized multicenter ALMANAC Trial. Journal of Clinical Oncology, 2004, 22, 506-506.	0.8	5
265	Psychosocial aspects of risk appraisal. Breast Cancer Research, 2008, 10, S14.	2.2	4
266	Too Hot, Too Cold or Can We Get it Just Right? What Emotional Distance Should Oncologists Keep from their Patients?. Clinical Oncology, 2017, 29, 205-206.	0.6	4
267	A new paradigm or a misrepresentation of current communication research and teaching?. Medical Education, 2017, 51, 1289-1290.	1.1	4
268	The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy and Technology, 2019, 8, 75-83.	1.3	4
269	Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing. Breast Cancer Research and Treatment, 2020, 184, 491-498.	1.1	4
270	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. Trials, 2021, 22, 173.	0.7	4

#	Article	IF	CITATIONS
271	Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing. British Journal of Cancer, 2022, 127, 1116-1122.	2.9	4
272	Quality of Life in Breast Cancer-Results from 3 Cancer Research Campaign Studies. Acta Clinica Belgica, 1993, 48, 19-23.	0.5	3
273	Positive epoetin alfa effect on quality of life in anemic cancer patients receiving chemotherapy: results from a randomized placebo-controlled trial. European Journal of Cancer, 1999, 35, S360.	1.3	3
274	Discussing expensive anti-cancer drugs. British Journal of Health Care Management, 2011, 17, 206-212.	0.1	3
275	Specialist breast care and research nurses' attitudes to adjuvant chemotherapy in older women with breast cancer. European Journal of Oncology Nursing, 2012, 16, 78-86.	0.9	3
276	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 58-66.	1,1	3
277	The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 629-638.	1.1	3
278	The fallacy of large survival gains from lung metastasectomy in colorectal cancer. Lancet, The, 2021, 397, 97-98.	6.3	3
279	Quality of Life Issues During Adjuvant Endocrine Therapy. Cancer Treatment and Research, 2009, 151, 353-365.	0.2	3
280	Patient/oncologist decisions about adjuvant chemotherapy in ER+ve, HER2-ve early breast cancer following endopredict testing Journal of Clinical Oncology, 2017, 35, e12002-e12002.	0.8	3
281	P126 Routes of administration in breast cancer:Preliminary findings from a patient survey. Breast, 2005, 14, S51.	0.9	2
282	Why patient recorded outcomes should be mandatory in and outside clinical trials to guide management of patients with metastatic breast cancer. Breast Cancer Research, 2007, 9, .	2.2	2
283	What should women do in the meantime?. BMJ: British Medical Journal, 2011, 343, d7544-d7544.	2.4	2
284	Enhancing your †webside†manner: communication during <scp>COVID</scp> â€19. Trends in Urology & Men's Health, 2021, 12, 12-15.	0.2	2
285	Doctors' communication of trust, care, and respect. BMJ: British Medical Journal, 2004, 328, 1317.2-1318.	2.4	2
286	What is newsworthy?. BMJ: British Medical Journal, 2002, 325, 774a-774.	2.4	2
287	An online review of informational sources for advanced or high-risk cutaneous squamous cell carcinoma. Supportive Care in Cancer, 2021, 29, 4199-4207.	1.0	1
288	The Prospective Observational Cohort and the Nested Randomized Controlled Trial in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC Study) Question the Reliance on Existing Evidence for the Magnitude of Benefit From Lung Metastasectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 502-503.	0.6	1

#	Article	IF	Citations
289	The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care Journal of Clinical Oncology, 2016, 34, 78-78.	0.8	1
290	Evaluation of counselling in the National Health Service. Journal of the Royal Society of Medicine, 1993, 86, 429-30.	1.1	1
291	Communication and counselling needs of patients with lymphoma. British Journal of Hospital Medicine, 1994, 52, 70-3.	0.0	1
292	Introduction to the sessions on 'Debate: Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors'. Breast Cancer Research, 2008, 10, S6.	2.2	0
293	Adherence to hormone therapy in a chemoprevention randomised trial. Breast Cancer Research, 2008, 10, .	2.2	0
294	Sensitivity and Specificity of Multimodal and Ultrasound Screening for Ovarian Cancer, and Stage Distribution of Detected Cancers: Results of the Prevalence Screen of the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Obstetrical and Gynecological Survey, 2009, 64, 592-593.	0.2	0
295	Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. Journal of the National Cancer Institute, 2010, 102, 207-208.	3.0	0
296	Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. Journal of Clinical Oncology, 2016, 34, 201-202.	0.8	0
297	Reply to â€~Comment on "The myth of pulmonary metastasectomy'― British Journal of Cancer, 2020, 12 1835-1836.	²³ 2.9	0
298	ARIX: A randomized trial of acupuncture versus oral care sessions in patients with chronic radiation-induced xerostomia following treatment for head and neck cancer Journal of Clinical Oncology, 2012, 30, 5527-5527.	0.8	0
299	Psychosocial issues in breast cancer. , 2014, , 258-267.		0
300	What's in a name: Describing ductal carcinoma in situ (DCIS) Journal of Clinical Oncology, 2014, 32, e12020-e12020.	0.8	0
301	Communicating the oncotype DX® test results: A novel educational workshop for specialist breast care nurses. European Journal of Oncology Nursing, 2020, 49, 101843.	0.9	0
302	IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer. Breast Cancer Research and Treatment, 2022, 192, 265-271.	1.1	0